Brought to you by 
Oncothyreon buys Alpine Biosciences for $26.2mm in stock
30 Sep 2020
Executive Summary
Cancer therapeutics developer Oncothyreon Inc. issued 9.3mm of its common shares (valued at $26.2mm based on the market average) to acquire Alpine Biosciences Inc., a privately held company utilizing a nanotechnology platform to develop targeted treatments for cancer and rare diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncothyreon buys Alpine Biosciences for $26.2mm in stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice